Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232282 | 0.90 | MMP2 (0.42) | CHRNA7 | |
| SCHEMBL12233834 | 0.89 | GRIN2D (0.48) | SMN1; SMN2MAPT | |
| SCHEMBL12232812 | 0.86 | ADAMTS5 (0.46) | SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL12232285 | 0.84 | ADAMTS5 (0.44) | SMN1; SMN2RAB9ATP53POLBMAPT | |
| SCHEMBL12232679 | 0.84 | ALDH1A1 (0.51) | SMN1; SMN2TP53MAPT | |
| SCHEMBL12232286 | 0.84 | CHRNA7 (0.42) | CHRNA7 | |
| SCHEMBL12232536 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ATP53POLB | |
| SCHEMBL12232646 | 0.81 | GRIN2D (0.57) | — | |
| SCHEMBL12232523 | 0.79 | LRRK2 (0.42) | SMN1; SMN2RAB9ATP53POLBMAPT | |
| SCHEMBL12232809 | 0.79 | SLC1A2 (0.45) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | GRIN2C, NR2C2, GRIN3A | SMN1; SMN2 3828/4885NPC1 1696/4885RAB9A 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.